Juno Therapeutics
Last updated: October 02, 2025
Hans Bishop, CEO
Country: USA | Funding: $310M (+)
Website: http://junotherapeutics.com/#no
Juno Therapeutics is a clinical-stage company developing novel cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Our goal is to revolutionize medicine by re-engaging the body’s immune system to treat cancer. Acquired by Celgene
Website: http://junotherapeutics.com/#no
Juno Therapeutics is a clinical-stage company developing novel cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Our goal is to revolutionize medicine by re-engaging the body’s immune system to treat cancer. Acquired by Celgene
